{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:07:33Z","timestamp":1786975653984,"version":"build-2736575974"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Myasthenia gravis (MG) is a chronic autoimmune disease that significantly impairs patients\u2019 quality of life by causing fluctuating muscle weakness and fatigue. While pharmacological treatment with corticosteroids remains a cornerstone of treatment, long-term use is often associated with substantial adverse effects. Although thymectomy is an established and effective alternative and adjunct to pharmacological treatment, its long-term cost-effectiveness within the UK National Health Service (NHS) is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the cost-effectiveness of thymectomy in addition to prednisolone therapy compared with prednisolone therapy alone for patients with nonthymomatous MG.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This economic evaluation used a Markov state-transition model to simulate the costs and health outcomes of patients with nonthymomatous MG. The patients\u2019 baseline characteristics, disease progression, and treatment efficacy were derived from patient-level data from the Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (MGTX) clinical trial. The model adopted a UK NHS and Personal Social Services perspective over a lifetime horizon. Data analysis was performed from June 2024 to October 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were incremental costs and quality-adjusted life years (QALYs) discounted at 3.5% per annum and the incremental cost-effectiveness ratio (ICER). Extensive deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the findings to parameter uncertainty.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 126 participants in the MGTX trial, with a mean age of 35.08 years; 70.63% were female. In the base-case analysis, thymectomy plus prednisolone dominated prednisolone alone, yielding higher health gains (14.63 QALYs vs 14.11 QALYs) and lower lifetime costs (\u00a3181\u202f716 vs \u00a3194\u202f730). This generated an incremental gain of 0.52 QALYs and a cost saving of \u00a313\u202f014 per patient. The results were robust across a wide range of sensitivity analyses. Probabilistic analysis (1000 simulations) showed that thymectomy had a greater than 99% probability of being cost-effective at a willingness-to-pay threshold of \u00a325\u202f000 per QALY.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this economic evaluation, thymectomy was found to be a highly cost-effective intervention for nonthymomatous MG in the UK and likely to be cost-saving relative to prednisolone alone. These findings support current clinical guidelines recommending thymectomy for eligible patients and establish it as the most relevant comparator in evaluations of future health technologies. More broadly, this study demonstrates the importance of high-quality randomized clinical trial evidence in enabling health technology assessment of surgical procedures.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.6612","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:30:31Z","timestamp":1776094231000},"page":"e266612","source":"Crossref","is-referenced-by-count":2,"title":["Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia Gravis"],"prefix":"10.1001","volume":"9","author":[{"given":"Joseph","family":"Lord","sequence":"first","affiliation":[{"name":"Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, United Kingdom"},{"name":"Centre for Reviews and Dissemination (CRD), University of York, Alcuin College, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination (CRD), University of York, Alcuin College, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Murphy","sequence":"additional","affiliation":[{"name":"LSE Health, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination (CRD), University of York, Alcuin College, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences\/SUNY, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Sussman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Greater Manchester Neuroscience Centre, Salford, Greater Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Department of Neurology & Rehabilitation Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Aban","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Hamedani","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination (CRD), University of York, Alcuin College, York, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"26","key":"zoi260224r1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis.","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260224r2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"issue":"4","key":"zoi260224r3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis.","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve"},{"issue":"2","key":"zoi260224r4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis.","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"zoi260224r5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","article-title":"The lived experience of myasthenia gravis: a patient-led analysis.","volume":"10","author":"Law","year":"2021","journal-title":"Neurol Ther"},{"issue":"6","key":"zoi260224r6","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient\u2019s perspective.","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"issue":"6","key":"zoi260224r7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy.","volume":"31","author":"Sacc\u00e0","year":"2024","journal-title":"Eur J Neurol"},{"issue":"3","key":"zoi260224r8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines.","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol"},{"key":"zoi260224r9","doi-asserted-by":"publisher","DOI":"10.17161\/rrnmf.v4i3.19548","author":"Remijn-Nelissen","year":"2023","journal-title":"RRNMF Neuromuscular J"},{"issue":"11","key":"zoi260224r10","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review.","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"10","key":"zoi260224r11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"issue":"2","key":"zoi260224r12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","article-title":"Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids.","volume":"30","author":"Tannemaat","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"zoi260224r13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1010-7940(99)00052-4","article-title":"Thymectomy for myasthenia gravis: a 27-year experience.","volume":"15","author":"Venuta","year":"1999","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"zoi260224r14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0003-4975(96)00376-1","article-title":"Extended thymectomy for myasthenia gravis patients: a 20-year review.","volume":"62","author":"Masaoka","year":"1996","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"zoi260224r15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008111.pub2","article-title":"Thymectomy for non-thymomatous myasthenia gravis.","volume":"2013","author":"Cea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"zoi260224r16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis.","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260224r17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"issue":"2","key":"zoi260224r18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1590\/S0124-00642012000200007","article-title":"The cost-effectiveness of open or thoracoscopic thymectomy compared to medical treatment in managing myasthenia gravis without thymomas.","volume":"14","author":"Chicaiza-Becerra","year":"2012","journal-title":"Rev Salud Publica (Bogota)"},{"issue":"6","key":"zoi260224r19","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.athoracsur.2020.01.047","article-title":"Transcervical thymectomy is the most cost-effective surgical approach in myasthenia gravis.","volume":"109","author":"Sholtis","year":"2020","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"zoi260224r20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/0272989X12454941","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20132.","volume":"32","author":"Roberts","year":"2012","journal-title":"Med Decis Making"},{"key":"zoi260224r22","doi-asserted-by":"publisher","DOI":"10.1177\/23814683211061097","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","author":"Husereau","year":"2022","journal-title":"MDM Policy Pract"},{"issue":"11","key":"zoi260224r23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.226340.182","article-title":"PONM09 thymectomy: its role in the management of myasthenia gravis.","volume":"81","author":"Spillane","year":"2010","journal-title":"J Neurol Neurosurgery Psychiatry"},{"issue":"5","key":"zoi260224r25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial.","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"issue":"18","key":"zoi260224r28","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"zoi260224r35","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases.","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"zoi260224r37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.21037\/gs-22-83","article-title":"Assessment of length of stay and cost of minimally invasive versus open thymectomies in patients with myasthenia gravis in Florida.","volume":"11","author":"Castillo-Larios","year":"2022","journal-title":"Gland Surg"},{"issue":"4","key":"zoi260224r38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.surg.2020.04.037","article-title":"Comparative effectiveness and cost-efficiency of surgical approaches for thymectomy.","volume":"168","author":"Imielski","year":"2020","journal-title":"Surgery"},{"issue":"6","key":"zoi260224r41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20136.","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"issue":"8","key":"zoi260224r42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i08","article-title":"Multi-state models for panel data: the msm package for R.","volume":"38","author":"Jackson","year":"2011","journal-title":"J Stat Softw"},{"issue":"6","key":"zoi260224r43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36)\u2014conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"3","key":"zoi260224r44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jhealeco.2006.09.002","article-title":"Modelling SF-6D health state preference data using a nonparametric Bayesian method.","volume":"26","author":"Kharroubi","year":"2007","journal-title":"J Health Econ"},{"issue":"7","key":"zoi260224r45","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1524-4733.2008.00352.x","article-title":"Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available).","volume":"11","author":"Ara","year":"2008","journal-title":"Value Health"},{"issue":"1","key":"zoi260224r46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"4","key":"zoi260224r47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available.","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"issue":"1","key":"zoi260224r48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.7555\/JBR.27.20120060","article-title":"Surgical approaches for stage I and II thymoma-associated myasthenia gravis: feasibility of complete video-assisted thoracoscopic surgery (VATS) thymectomy in comparison with trans-sternal resection.","volume":"27","author":"He","year":"2013","journal-title":"J Biomed Res"},{"issue":"2","key":"zoi260224r49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jtcvs.2019.11.114","article-title":"A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma.","volume":"160","author":"Yang","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"zoi260224r34","author":"Canada's Drug Agency","year":"2020"},{"key":"zoi260224r40","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"zoi260224r21","unstructured":"National Institute for Health and Care Excellence. Nice health technology evaluations: the manual. January 31, 2022. Accessed March 3, 2026. https:\/\/www.nice.org.uk\/process\/pmg36"},{"key":"zoi260224r24","unstructured":"Canada\u2019s Drug Agency. Cadth Common Drug Review: clinical review report: Eculizumab (soliris). October 2020. Accessed March 3, 2026. https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/clinical\/sr0640-soliris-nmosd-clinical-review-report.pdf"},{"key":"zoi260224r26","unstructured":"Myasthenia Gravis Foundation of America. Resources for professionals. Accessed March 3, 2026. https:\/\/myasthenia.org\/Professionals\/Resources-for-Professionals\/"},{"key":"zoi260224r27","unstructured":"National Institute for Health and Care Excellence. Efgartigimod for treating generalised myasthenia gravis. June 4, 2025. Accessed March 3, 2026. https:\/\/www.nice.org.uk\/guidance\/ta1069\/chapter\/1-Recommendation"},{"key":"zoi260224r29","unstructured":"National Institute for Health and Care Excellence. British National Formulary. Accessed March 3, 2026. https:\/\/bnf.nice.org.uk\/"},{"key":"zoi260224r30","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT). Accessed March 3, 2026. https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit"},{"key":"zoi260224r31","unstructured":"Jones? KC, Weatherly? H, Birch? S, . Unit costs of health and social care 2024 manual. Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York). Accessed March 11, 2026. https:\/\/kar.kent.ac.uk\/109563\/"},{"key":"zoi260224r32","unstructured":"NHS England. 2020\/21 National cost collection data. Accessed March 3, 2026. https:\/\/www.england.nhs.uk\/publication\/2020-21-national-cost-collection-data-publication\/"},{"key":"zoi260224r33","unstructured":"NHS England. 2022\/23 National cost collection data. Accessed March 3, 2026. https:\/\/www.england.nhs.uk\/publication\/2022-23-national-cost-collection-data-publication-2\/"},{"key":"zoi260224r36","unstructured":"Bank of England. Inflation calculator. Accessed March 3, 2026. https:\/\/www.bankofengland.co.uk\/monetary-policy\/inflation\/inflation-calculator"},{"key":"zoi260224r39","unstructured":"NHS England. 2023\/24 National cost collection data. Accessed March 3, 2026. https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"zoi260224r50","unstructured":"National Library of Medicine. Thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy. Updated May 23, 2017. Accessed March 3, 2026. https:\/\/clinicaltrials.gov\/study\/NCT00294658#contacts-and-locations"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847674\/lord_2026_oi_260224_1775496084.51992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:30:35Z","timestamp":1776094235000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.6612","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}